Houston M C, Thompson W L, Robertson D
Arch Intern Med. 1984 Jul;144(7):1433-9. doi: 10.1001/archinte.144.7.1433.
Recent investigations have underscored the great diversity in both the causes and manifestations of clinical shock. The emphasis has shifted toward more specific therapy when that has been possible. Pure vasoconstrictors have assumed a secondary therapeutic role, as volume replacement or expansion has become the initial management of shock. Agents, such as naloxone hydrochloride, corticosteroids, fructose diphosphate, amrinone and milrinone , and nonsteroidal antiinflammatory agents, while still experimental, offer improved understanding and management of the shock syndrome.
最近的研究强调了临床休克在病因和表现方面的巨大多样性。在可能的情况下，重点已转向更具针对性的治疗。由于补充或扩充血容量已成为休克的初始治疗方法，单纯的血管收缩剂已退居次要治疗地位。诸如盐酸纳洛酮、皮质类固醇、果糖二磷酸、氨力农和米力农等药物，以及非甾体类抗炎药，尽管仍处于试验阶段，但有助于更好地理解和治疗休克综合征。
